Levoleucovorin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2008
- First approval year
- 2008
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Levoleucovorin
- Molecular weight
- 473.45
- Structure (SMILES)
- Nc1nc(=O)c2c([nH]1)NC[C@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O
- khapzory
- Khapzory
- (6s)-leucovorin
- (s)-leucovorin
- 6s leucovorin
- l folinic acid
- l glutamic acid n 4 6s 2 amino 5 formyl 1 4 5 6 7 8 hexahydro 4 oxo 6 pteridinyl methyl amino benzoyl
- L-folinic acid
- L-Folinic acid
- L-GLUTAMIC ACID, N-(4-((((6S)-2-AMINO-5-FORMYL-1,4,5,6,7,8-HEXAHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)-
- levofolene
- Levofolene
- levofolinic acid
- Levofolinic acid
- Levofolinic acid [WHO-DD]
- Levofolinic Acid For Injection
- levofolinic acid who dd
- levoleucovorin
- Levoleucovorin
- LEVOLEUCOVORIN [ORANGE BOOK]
- LEVOLEUCOVORIN [VANDF]
- levoleucovorin orange book
- levoleucovorin vandf
- lfp 754
- LFP-754
- s leucovorin
- ChEMBL ID
- CHEMBL1908841
- InChIKey
- VVIAGPKUTFNRDU-STQMWFEESA-N
- PubChem compound IDs
- 135398559
- RxNorm IDs (RxCUI)
- 877015
- FDA ingredient codes (UNII)
- 990S25980Y
- 68538-85-2
- 80433-71-2
- Applicant
- ACROTECH BIOPHARMA
- Approval date
- 7 Mar 2008
- Application number
- NDA020140
- Patents
- 1
- Designations
- 2
- Earliest recorded loss of exclusivity
- 25 Mar 2039
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
Administration routes
- Parenteral
- Condition
- Osteosarcoma
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000637
- Subject identifier
- D012516
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004142
- Subject identifier
- D015179
- Condition
- Colonic Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004288
- Subject identifier
- D003110
- Condition
- Esophageal Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005922
- Subject identifier
- D004938
- Condition
- Rectal Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000657
- Subject identifier
- D012004
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:1001951
- Subject identifier
- D015179
- Condition
- Stomach Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0001056
- Subject identifier
- D013274
- Condition
- Anemia
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0002280
- Subject identifier
- D000740
- Condition
- Colorectal Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005575
- Subject identifier
- D015179
- Condition identifier
- EFO_0000637
- Condition identifier
- EFO_0004288
- Condition identifier
- EFO_1000044
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001480
- Highest recorded phase
- 3
- Condition identifier
- HP_0002014
- Highest recorded phase
- 3
- Condition identifier
- HP_0002018
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001056
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002280
- Condition identifier
- MONDO_0002280
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0003219
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004967
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005028
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005036
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005575
- Condition identifier
- MONDO_0005575
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005580
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0006519
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007256
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009807
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0019086
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0021063
- Highest recorded phase
- 3
- Event
- abdominal pain
- Reports
- 550
- Reporting signal score
- 200.906
- Event
- anaemia
- Reports
- 547
- Reporting signal score
- 190.883
- Event
- anaphylactic shock
- Reports
- 9
- Reporting signal score
- 14.0443
- Event
- cholinergic syndrome
- Reports
- 5
- Reporting signal score
- 22.0207
- Event
- colorectal cancer metastatic
- Reports
- 88
- Reporting signal score
- 288.934
- Event
- coombs direct test positive
- Reports
- 2
- Reporting signal score
- 8.52811
- Event
- decreased appetite
- Reports
- 437
- Reporting signal score
- 190.924
- Event
- dehydration
- Reports
- 447
- Reporting signal score
- 264.889
- Event
- dermatitis acneiform
- Reports
- 146
- Reporting signal score
- 323.703
- Event
- diarrhoea
- Reports
- 1,744
- Reporting signal score
- 1,005.05
- Event
- disease progression
- Reports
- 586
- Reporting signal score
- 600.541
- Event
- febrile neutropenia
- Reports
- 671
- Reporting signal score
- 904.662
- Event
- gastrointestinal toxicity
- Reports
- 104
- Reporting signal score
- 214.427
- Event
- general physical health deterioration
- Reports
- 318
- Reporting signal score
- 230.329
- Event
- haematotoxicity
- Reports
- 199
- Reporting signal score
- 387.818
- Event
- hyperammonaemia
- Reports
- 4
- Reporting signal score
- 8.74774
- Event
- hypertension
- Reports
- 479
- Reporting signal score
- 176.183
- Event
- hypertransaminasaemia
- Reports
- 4
- Reporting signal score
- 8.81495
- Event
- injection site pain
- Reports
- 3
- Reporting signal score
- 173.164
- Event
- interstitial lung disease
- Reports
- 10
- Reporting signal score
- 10.5599
- Event
- leukopenia
- Reports
- 367
- Reporting signal score
- 343.965
- Event
- malignant neoplasm progression
- Reports
- 264
- Reporting signal score
- 179.599
- Event
- metastases to liver
- Reports
- 183
- Reporting signal score
- 317.442
- Event
- monocytosis
- Reports
- 4
- Reporting signal score
- 17.0504
- Event
- mucosal inflammation
- Reports
- 437
- Reporting signal score
- 734.063
And 22 more, listed on the interactive page.
- NCT01383707
- NCT01718873
- NCT01895257
- NCT05839470
- NCT01481545
- NCT02280070
- NCT01590719
- NCT05319639
- NCT06197438
- NCT01681472
- NCT01836653
- NCT04949256
- NCT05253651
- Dose
- 7.5 mg (approximately 5 mg/m2)
- Route
- Intravenous
- How often
- Every 6 hours until methotrexate level is below 5 x 10-8 M
- Hydrogen bond acceptors
- 9
- Hydrogen bond donors
- 7
- Polar surface area
- 219.84
- Calculated partition coefficient (ALogP)
- -0.73
- Calculated partition coefficient (XLogP)
- -1.2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 10
- Heavy atoms
- 34
- Molecular formula
- C20H23N7O7
- Monoisotopic mass
- 473.16589610
- Natural product
- Yes
- Recorded assays
- 5
- Active assays
- 0
- Antidotes
Related records
Trials (24)
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer
- A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer
- A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
- Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
- Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
- Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
- Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
- Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
- New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
- Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers
- Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
- Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
- PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
- Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Approved for (5)
In development for (5)
- Colonic neoplasm Phase 1
- Esophageal squamous cell carcinoma Phase 3
- Gastric cancer Phase 2
- Pancreatic adenocarcinoma Phase 2
- Rectal cancer Phase 2